Imugene Entered into a Clinical Trial Supply Agreement with Roche to Evaluate PD1-Vaxx + Atezolizumab for the Treatment of Lung Cancer

Published: Jan 28, 2022 | Tags: Imugene, Roche, PD1-Vaxx, Atezolizumab, Lung Cancer

Aurealis Entered into an Exclusive License and Collaboration Agreement with Xbiome for AUP-16 to Treat Diabetic Foot Ulcer and Inflammatory Disease

Published: Jan 28, 2022 | Tags: Aurealis, Xbiome, AUP-16, Diabetic Foot Ulcer, Inflammatory Disease

4D pharma Reports Results of MRx-4DP0004 in Part A of the P-I/II Trial for the Treatment of Asthma

Published: Jan 28, 2022 | Tags: 4D Pharma, MRx-4DP0004, Part A, P- I/II Trial, Asthma

Adagene Reports First Patient Dosing of ADG106 + ADG116 in P-Ib/II (ADG116-1003) Trial for the Treatment of Solid Tumors

Published: Jan 28, 2022 | Tags: Adagene, ADG106, ADG116, P-Ib/II, ADG116-1003 Trial, Solid Tumors

BridgeBio Reports First Patient Dosing in P-I/II (ADventure) Trial for the Treatment of Congenital Adrenal Hyperplasia

Published: Jan 28, 2022 | Tags: BridgeBio, P-I/II, ADventure Trial, Congenital Adrenal Hyperplasia

Pfizer’s Receives EMA's CHMP Positive Opinion Recommending Conditional Marketing Authorization of Paxlovid (nirmatrelvir and ritonavir) for COVID-19

Published: Jan 28, 2022 | Tags: Pfizer’s Paxlovid Receives CHMP Positive Opinion for the Treatment of COVID-19

Merck’s Keytruda (pembrolizumab) Receives EC’s Approval as an Adjuvant Treatment for Renal Cell Carcinoma

Published: Jan 27, 2022 | Tags: Merck, Keytruda, pembrolizumab, EC, Approval, Renal Cell Carcinoma

Sierra Oncology Reports Results of Momelotinib in P-III (MOMENTUM) Study for the Treatment of Myelofibrosis

Published: Jan 27, 2022 | Tags: Sierra Oncology, Momelotinib, P-III, MOMENTUM Study, Myelofibrosis

Immunocore’s Kimmtrak (tebentafusp-tebn) Receives the US FDA’s Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma

Published: Jan 27, 2022 | Tags: Immunocore, Kimmtrak, tebentafusp-tebn, US, FDA, Approval, for Uveal Melanoma

Imara Reports the US FDA’s IND Clearance of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction

Published: Jan 27, 2022 | Tags: Imara, US, FDA, IND, Tovinontrine, IMR-687, Heart Failure, Preserved Ejection Fraction

Gilead Reports the US FDA's Clinical Hold on Multiple Studies of Magrolimab + Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published: Jan 27, 2022 | Tags: Gilead, US, FDA, Clinical Hold, Magrolimab, Azacitidine, Myelodysplastic Syndrome, Acute Myeloid Leukemia

Checkpoint Reports Results of Cosibelimab in Registration-Enabling Trial for Metastatic Cutaneous Squamous Cell Carcinoma

Published: Jan 27, 2022 | Tags: Checkpoint Therapeutics, Cosibelimab, Metastatic Cutaneous Squamous Cell Carcinoma

Lundbeck’s Vyepti (eptinezumab) Receives EC’s Approval for the Treatment of Migraine

Published: Jan 25, 2022 | Tags: Lundbeck, Vyepti, eptinezumab, EC, Approval, Migraine

Horizon Reports First Patient Enrollment of HZN-825 in P-IIb Trial for the Treatment of Idiopathic Pulmonary Fibrosis

Published: Jan 25, 2022 | Tags: Horizon, HZN-825, P-IIb Trial, Idiopathic Pulmonary Fibrosis

Genentech’s Evrysdi (risdiplam) Receives the US FDA’s Priority Review of sNDA for the Treatment of Spinal Muscular Atrophy

Published: Jan 25, 2022 | Tags: Genentech, Evrysdi, risdiplam, US, FDA, Priority Review, sNDA, Spinal Muscular Atrophy

Karyopharm’s Eltanexor Receives the US FDA’s Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes.

Published: Jan 25, 2022 | Tags: Karyopharm, Eltanexor, US, FDA, Orphan Drug Designation, Myelodysplastic Syndromes

Genentech Publishes Results of Faricimab in Multiple Trials for the Treatment of AMD and DME in The Lancet

Published: Jan 25, 2022 | Tags: Genentech, Faricimab, AMD, DME, Lancet

Deciphera Presents Results of Qinlock (ripretinib) in P-III (INTRIGUE) Study for the Treatment of Gastrointestinal Stromal Tumor at ASCO 2022

Published: Jan 25, 2022 | Tags: Deciphera, Qinlock, ripretinib, P-III, INTRIGUE Study, Gastrointestinal Stromal Tumor, ASCO 2022

Ascletis Reports First Patient Dosing in the P-III Clinical Trial of ASC40 + Bevacizumab for Treatment of Recurrent Glioblastoma

Published: Jan 24, 2022 | Tags: Ascletis, P-III Clinical Trial, ASC40, Bevacizumab, Recurrent Glioblastoma

Verona Pharma Reports Completion of Enrollment for Ensifentrine in P-III (ENHANCE-2) Trial to Treat COPD

Published: Jan 24, 2022 | Tags: Verona Pharma, Ensifentrine, P-III, ENHANCE-2 Trial, COPD

Gilead’s Veklury (remdesivir) Receives the US FDA’s Approval for the Treatment of COVID-19

Published: Jan 24, 2022 | Tags: Gilead, Veklury, remdesivir, US, FDA, Approval, COVID-19

Alnylam Presents 18-Month Results of Vutrisiran in P-III (HELIOS-A) Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Published: Jan 24, 2022 | Tags: Alnylam, Vutrisiran, P-III, HELIOS-A Study, hATTR Amyloidosis, Polyneuropathy

AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval for the Treatment of Active Psoriatic Arthritis

Published: Jan 24, 2022 | Tags: AbbVie, Skyrizi, risankizumab-rzaa, US, FDA, Approval, Active Psoriatic Arthritis

Innovent and Eli Lilly Present Results of P-Ib Study of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) for Advanced Hepatocellular Carcinoma at ASCO GI 2022

Published: Jan 24, 2022 | Tags: Innovent, Eli Lilly, P-Ib Study, Tyvyt, sintilimab, Byvasda, biosimilar, bevacizumab, Hepatocellular Carcinoma, ASCO GI 2022

Related Post: PharmaShots Weekly Snapshots (January 17 - 21, 2022)